Litigation Note: Crowell & Moring Secures IP Victory for Apotex
Firm News | less than 1 min read | 10.01.15
Washington, D.C. - October 1, 2015: Crowell & Moring represented Apotex in successfully challenging the validity of U.S. Patent No. 8,324,283 before the U.S. Patent and Trademark Office Patent Trial and Appeals Board (PTAB). Apotex, along with generic pharmaceutical companies Torrent Pharmaceuticals and Mylan Pharmaceuticals, petitioned the PTAB to invalidate the '283 patent related to oral formulations for the administration of the multiple sclerosis drug fingolimod, marketed by Novartis as Gilenya®. As a result, all claims of the '283 patent were found invalid by PTAB.
Insights
Firm News | 2 min read | 04.26.24
The Los Angeles Business Journal Names Valerie Goo to Top 100 Lawyers 2024
The Los Angeles Business Journal has named Crowell & Moring partner Valerie M. Goo to its list of Top 100 Lawyers 2024.
Firm News | 2 min read | 04.18.24
Global Public Affairs Executive Mark Elliot Joins Crowell & Moring International
Firm News | 3 min read | 04.18.24
Highly Respected Corporate Team Joins Crowell’s Chicago Office